Q1 2021 Report and presentation

Tromsø, Norway, 22 April 2021 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 40.4 million (18.5) and an EBITDA of NOK 25.8 million (9.0) for the first quarter of 2021. Highlights from Q1 2021 ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by 119% (Q1 2020: NOK 18.5 million) Coronavirus-related sales are estimated at NOK 16.5 …

ArcticZymes Technologies ASA: Invitation to presentation of Q1 2021 results

ArcticZymes Technologies presents its report for the first quarter 2021 on Thursday, 22. April 2021 at 08.30 a.m. Due to the ongoing situation with spread of coronavirus, a number of measures are being implemented to prevent the spread of infection. These measures are being taken to safeguard the health and security of the Company’s shareholders, employees and other stakeholders, and …

ArcticZymes Technologies Successfully Upscales SAN HQ Enzyme Production

Tromsø, Norway, 26th March 2021 – ArcticZymes Technologies ASA (OSE: AZT) announces it has successfully scaled-up the manufacturing of its SAN HQ enzyme ArcticZymes Technologies´ Salt Active Nuclease High Quality (SAN HQ) enzyme offers gene therapy and vaccine customers a more cost effective and technically superior solution for the removal of contaminating DNA during the manufacturing process of therapeutic viruses. …

Q4 2020 Report and presentation

Tromsø, Norway, 28 January 2021 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 22.1 million (16.3) and an EBITDA of NOK 6.8 million (4.9) for the fourth quarter of 2020. Underlying growth continues. Highlights from Q4 2020 All financials figures are exclusive of discontinued operations (Biotec BetaGlucans) ArcticZymes Technologies had Q4 sales of NOK 22.1 million growing by 35% …